Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 239

Results For "patients"

3865 News Found

Modi to dedicate three National Ayush Institutes to the nation on Dec 11
Policy | December 08, 2022

Modi to dedicate three National Ayush Institutes to the nation on Dec 11

These satellite institutes will further strengthen the research, international collaborations and facilitate affordable Ayush services for the larger community.


Telemedicine service eSanjeevani achieves 8 crore teleconsultations
News | December 07, 2022

Telemedicine service eSanjeevani achieves 8 crore teleconsultations

The initiative has garnered the distinction of being the world’s largest government owned telemedicine platform


JB Pharma reduces price of Azmarda by 50%
News | December 06, 2022

JB Pharma reduces price of Azmarda by 50%

Move to increase affordability and accessibility for heart failure patients across the country


Biocon Biologics elevates Shreehas Tambe as MD & CEO
People | December 06, 2022

Biocon Biologics elevates Shreehas Tambe as MD & CEO

Tambe has been with Biocon since 1997 and has held diverse leadership and operational roles.


ANSSI Wellness inaugurates its new spine clinic in Pune
Healthcare | December 06, 2022

ANSSI Wellness inaugurates its new spine clinic in Pune

Asia’s premier and USA-patented, ANSSI Wellness for spinal decompression was launched in Pune


ASG Eye Hospitals opens hospital in Vashi
Healthcare | December 06, 2022

ASG Eye Hospitals opens hospital in Vashi

The new eye hospital in Vashi is ASG’s second in the Mumbai Metropolitan Region (MMR) and the sixth in Maharashtra


Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study
News | December 05, 2022

Mirati Therapeutics announces update for the Phase 3 SAPPHIRE study

Evaluating Investigational Sitravatinib in combination with Nivolumab for patients with non-squamous non-small cell lung cancer


Merck to present data from Its hematology portfolio ASH meeting
News | December 05, 2022

Merck to present data from Its hematology portfolio ASH meeting

Presentations include new data on investigational medicines – favezelimab (MK-4280), zilovertamab vedotin (MK-2140) and nemtabrutinib – as well as KEYTRUDA (pembrolizumab) in multiple blood cancers


Jemperli RUBY phase III trial met its primary endpoint
Clinical Trials | December 05, 2022

Jemperli RUBY phase III trial met its primary endpoint

Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival